Inventor · disambiguated record
Ahmed Abdi Samatar
Also filed as: SAMATAR AHMED · SAMATAR AHMED A · SAMATAR AHMED ABDI
12 granted patents·24 pending applications·16 citations·filing 2006–2025
86Inventor score
Files withRECURIUM IP HOLDINGS LLC26COOPER ALAN B2SLAP PHARMACEUTICALS LLC2ZENO MAN INC2COOPER ALAN1
Top patents by PatentIndex Score
36 records- 0196US11813260B1Benzamide compoundsRECURIUM IP HOLDINGS LLC·Filed 2023·Granted Nov 14, 2023·1 cites·20 claims
- 0293US11813259B2Benzamide compoundsRECURIUM IP HOLDINGS LLC·Filed 2022·Granted Nov 14, 2023·1 cites·17 claims
- 0389US2024180899A1Benzamide compoundsRECURIUM IP HOLDINGS LLC·Filed 2023·Application pending·0 cites
- 0487US11590126B2Benzamide compoundsRECURIUM IP HOLDINGS LLC·Filed 2019·Granted Feb 28, 2023·1 cites·97 claims
- 0587US11344546B2Benzamide compoundsRECURIUM IP HOLDINGS LLC·Filed 2019·Granted May 31, 2022·1 cites·109 claims
- 0686US8546404B2Compounds that are ERK inhibitorsCOOPER ALAN B·Filed 2007·Granted Oct 1, 2013·9 cites·76 claims
- 0781US11278532B2Estrogen receptor modulators for treating mutantsRECURIUM IP HOLDINGS LLC·Filed 2020·Granted Mar 22, 2022·1 cites·22 claims
- 0874US11318134B2Benzamide compoundsRECURIUM IP HOLDINGS LLC·Filed 2019·Granted May 3, 2022·0 cites·82 claims
- 0973US8716483B2Compounds that are ERK inhibitorsCOOPER ALAN B·Filed 2009·Granted May 6, 2014·2 cites·12 claims
- 1069USRE50643EBenzamide compoundsRECURIUM IP HOLDINGS LLC·Filed 2019·Granted Oct 21, 2025·0 cites·100 claims
- 1169US12054479B1Multicyclic compoundsSLAP PHARMACEUTICALS LLC·Filed 2024·Granted Aug 6, 2024·0 cites·4 claims
- 1266US2024261295A1Combinations of wee1 inhibitors and anti-cd47 antibodiesRECURIUM IP HOLDINGS LLC·Filed 2024·Application pending·0 cites
- 1364US2024299395A1Combination therapies comprising wee1 inhibitors and dna damage response (ddr) inhibitorsRECURIUM IP HOLDINGS LLC·Filed 2024·Application pending·0 cites
- 1464US2024325397A1Use of combination therapy for treating cancerRECURIUM IP HOLDINGS LLC·Filed 2024·Application pending·0 cites
- 1563US2024335447A1Wee1 inhibitor for cancerRECURIUM IP HOLDINGS LLC·Filed 2024·Application pending·0 cites
- 1661US2024408097A1Wee1 inhibitors and methods for treating cancerRECURIUM IP HOLDINGS LLC·Filed 2023·Application pending·0 cites
- 1761US2022125769A1Estrogen receptor modulators for treating mutantsRECURIUM IP HOLDINGS LLC·Filed 2022·Application pending·0 cites
- 1859US2025214980A1Multicyclic compoundsSLAP PHARMACEUTICALS LLC·Filed 2023·Application pending·0 cites
- 1958US2024197743A1Wee1 compound for treating uterine serous carcinomaRECURIUM IP HOLDINGS LLC·Filed 2022·Application pending·0 cites
- 2056US2011158944A1Braf biomarkersHOSTED THOMAS J·Filed 2008·Application pending·0 cites
- 2156US2023381172A1Combinations of bcl-2 inhibitors with chemotherapeutic agentsRECURIUM IP HOLDINGS LLC·Filed 2021·Application pending·0 cites
- 2254US2023210854A1Mono- and combination therapiesRECURIUM IP HOLDINGS LLC·Filed 2021·Application pending·0 cites
- 2354US2023158048A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2021·Application pending·0 cites
- 2453US2023065577A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 2552US2023054854A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 2652US2023068370A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 2751US2023210846A1Treatment for amyloidosisZENO MAN INC·Filed 2021·Application pending·0 cites
- 2851US2023054767A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 2951US2023008362A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 3050US2023042653A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 3150US2023053946A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 3249US2023087941A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 3346US2025262214A1Intermittent dosing regimen for azenosertib in treating cancerZENO MAN INC·Filed 2025·Application pending·0 cites
- 3441US2007191604A1Novel compounds that are ERK inhibitorsCOOPER ALAN·Filed 2006·Application pending·0 cites
- 3540US9229008B2IL-8 level as a determinant of responsivity of a cancer to treatmentMERCK SHARP & DOHME·Filed 2013·Granted Jan 5, 2016·0 cites·21 claims
- 3636US8586543B2IL-8 biomarker for monitoring cancer treatment with certain ERK inhibitorsSAMATAR AHMED A·Filed 2009·Granted Nov 19, 2013·0 cites·24 claims
Join the waitlist — get patent alerts
Get an alert when Ahmed Abdi Samatar files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →